Sunday, July 12, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 52 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 10087181

    Compound as WNT signaling inhibitor, composition, and use thereof

    Curegenix, Inc. · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted

  2. US 10080740

    Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

    Aurigene Discovery Technologies Limited · Granted Sep 25, 2018 · Expires Sep 20, 2038

    granted

  3. US 10081632

    Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors

    PHOENIX MOLECULAR DESIGNS · Granted Sep 25, 2018 · Expires Sep 20, 2038

    granted

  4. US 10080745

    Piericidin bacterial inhibitors

    The Regents of the University of California Santa Cruz · Granted Sep 25, 2018 · Expires Sep 20, 2038

    granted

  5. US 10077273

    SHMT inhibitors

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Sep 18, 2018 · Expires Sep 13, 2038

    granted

  6. US 10076520

    Use of tyrosine kinase inhibitor in cancer treatment

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 18, 2018 · Expires Sep 13, 2038

    granted

  7. US 10076571

    Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 18, 2018 · Expires Sep 13, 2038

    granted

  8. US 10076521

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Sep 18, 2018 · Expires Sep 13, 2038

    granted

  9. US 10071976

    Small molecule fatty acid synthase inhibitors

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted

  10. US 10064844

    Pharmaceutical compositions comprising an aromatse inhibitors

    MEREO BIOPHARMA 2 LIMITED · Granted Sep 4, 2018 · Expires Aug 30, 2038

    granted

  11. US 10059668

    LSD1 inhibitors

    Mirati Therapeutics, Inc. · Granted Aug 28, 2018 · Expires Aug 23, 2038

    granted

  12. US 10053417

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Aug 21, 2018 · Expires Aug 16, 2038

    granted

  13. US 10047104

    Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

    Aurigene Discovery Technologies Limited · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted

  14. US 10045990

    ERBB4 inhibitors and methods of use thereof

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted

  15. US 10040766

    Ubiquitination inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Aug 7, 2018 · Expires Aug 2, 2038

    granted

  16. US 10040769

    HDAC inhibitors for the treatment of diabetic peripheral neuropathy

    Regenacy Pharmaceuticals, Inc. · Granted Aug 7, 2018 · Expires Aug 2, 2038

    granted

  17. US 10039802

    Methods of treating chronic disorders with complement inhibitors

    Apellis Pharmaceuticals, Inc. · Granted Aug 7, 2018 · Expires Aug 2, 2038

    granted

  18. US 10039762

    Inhibitors of influenza viruses replication

    Vertex Pharmaceuticals Incorporated · Granted Aug 7, 2018 · Expires Aug 2, 2038

    granted

  19. US 10035824

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted

  20. US 10028960

    Pyrimidine compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jul 24, 2018 · Expires Jul 19, 2038

    granted

  21. US 10030024

    Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway

    Vertex Pharmaceuticals Incorporated · Granted Jul 24, 2018 · Expires Jul 19, 2038

    granted

  22. US 10029988

    HDAC inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Jul 24, 2018 · Expires Jul 19, 2038

    granted

  23. US 10022364

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  24. US 10023569

    Methods of preparing inhibitors of influenza viruses replication

    Vertex Pharmaceuticals Incorporated · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.